0001640334-24-000334.txt : 20240301
0001640334-24-000334.hdr.sgml : 20240301
20240301200819
ACCESSION NUMBER: 0001640334-24-000334
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240228
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: EMANUELE ROBERT MARTIN
CENTRAL INDEX KEY: 0001184991
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38951
FILM NUMBER: 24712493
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARTELO BIOSCIENCES, INC.
CENTRAL INDEX KEY: 0001621221
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 331220924
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 LOMAS SANTA FE, SUITE 160
CITY: SOLANA BEACH
STATE: CA
ZIP: 92075
BUSINESS PHONE: 858-925-7049
MAIL ADDRESS:
STREET 1: 505 LOMAS SANTA FE, SUITE 160
CITY: SOLANA BEACH
STATE: CA
ZIP: 92075
FORMER COMPANY:
FORMER CONFORMED NAME: REACTIVE MEDICAL INC.
DATE OF NAME CHANGE: 20170207
FORMER COMPANY:
FORMER CONFORMED NAME: KNIGHT KNOX DEVELOPMENT CORP.
DATE OF NAME CHANGE: 20141001
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0508
4
2024-02-28
0
0001621221
ARTELO BIOSCIENCES, INC.
ARTL
0001184991
EMANUELE ROBERT MARTIN
505 LOMAS SANTA FE, SUITE 160
SOLANA BEACH
CA
92075
1
0
0
0
0
Stock Option (right to buy)
162
2024-02-28
4
D
0
834
D
2021-08-17
2028-08-17
Common Stock
834
0
D
Stock Option (right to buy)
29.85
2024-02-28
4
D
0
1167
D
2020-02-29
2029-08-29
Common Stock
1167
0
D
Stock Option (right to buy)
39.9
2024-02-28
4
D
0
8034
D
2023-02-12
2031-02-12
Common Stock
8034
0
D
Stock Option (right to buy)
15
2024-02-28
4
D
0
667
D
2022-06-23
2031-07-16
Common Stock
667
0
D
Stock Option (right to buy)
4.89
2024-02-28
4
D
0
667
D
2023-06-24
2032-06-24
Common Stock
667
0
D
Stock Option (right to buy)
1.99
2024-02-28
4
D
0
667
D
2033-06-30
Common Stock
667
0
D
Stock Option (right to buy)
2.01
2024-02-28
4
D
0
1083
D
2033-08-04
Common Stock
1083
0
D
Stock Option (right to buy)
1.55
2024-02-28
4
A
0
834
A
2028-08-17
Common Stock
834
834
D
Stock Option (right to buy)
1.55
2024-02-28
4
A
0
1167
A
2029-08-29
Common Stock
1167
1167
D
Stock Option (right to buy)
1.55
2024-02-28
4
A
0
8034
A
2031-02-12
Common Stock
8034
8034
D
Stock Option (right to buy)
1.55
2024-02-28
4
A
0
667
A
2031-07-16
Common Stock
667
667
D
Stock Option (right to buy)
1.55
2024-02-28
4
A
0
667
A
2032-06-24
Common Stock
667
667
D
Stock Option (right to buy)
1.55
2024-02-28
4
A
0
667
A
2033-06-30
Common Stock
667
667
D
Stock Option (right to buy)
1.55
2024-02-28
4
A
0
1083
A
2033-08-04
Common Stock
1083
1083
D
This option was granted on August 17, 2018 and was previously reported as covering 12,500 shares at an exercise price of $10.80 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.
The Reporting Person agreed to certain amendments of their outstanding stock option pursuant to the terms of a repricing and revesting offer approved by the Issuer's Compensation Committee of the Board of Directors (the "Offer") relating to a one-time offer by the Issuer to reprice and adjust the vesting of certain Eligible Options (as defined in the Offer).
This option was granted on August 29, 2019 and was previously reported as covering 17,500 shares at an exercise price of $1.99 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.
This option was granted on February 12, 2021 and was previously reported as covering 120,500 shares at an exercise price of $2.66 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.
This option was granted on July 16, 2021 and was previously reported as covering 10,000 shares at an exercise price of $1.00 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.
This option was granted on June 24, 2022 and was previously reported as covering 10,000 shares at an exercise price of $0.326 per share, but was adjusted to reflect a 1-for-15 reverse stock split that occurred on August 10, 2022.
Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's 2018 Equity Incentive Plan (the "Plan")) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean June 30, 2023.
Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean August 4, 2023.
Pursuant to the Offer, and subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one third (1/3rd) of the shares subject to the option shall vest on the first anniversary of the Amendment Date, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Amendment Date (or, if there is no such day, the last day of the month). "Amendment Date" shall mean February 28, 2024.
/s/ Gregory D. Gorgas, as Attorney-in-Fact
2024-03-01